Navigation Links
New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)

UPPSALA, Sweden and CAMBRIDGE, England, April 23 /PRNewswire/ -- Two leading companies in the area of fragment-based drug discovery (FBDD) today announced a new commercial alliance. IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Beactica AB, based in Uppsala, Sweden, will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.

The IOTA-Beactica platform couples comprehensive, site-directed FBDD libraries to state-of-the-art fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling the rapid progression of new discovery programs from concept to optimized lead.

Based on rapid determination of ligand-target interaction information, and using a unique combination of fragment-based drug screening and medicinal chemistry-led design approaches, applicable to a wide range of new targets, the platform will initially focus on the development of new classes of kinase inhibitors. The reagents, tools and technologies developed by the two companies will be commercialized through drug discovery partnerships with pharmaceutical companies active in the kinase area.

Dr Per Kallblad, CEO of Beactica, said, "We are delighted to work with IOTA to expand our existing drug discovery platform. The combination of IOTA's proprietary FBDD engine with Beactica's SPR screening technology will be an excellent way to pursue the discovery and optimization of new kinase inhibitors."

Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to NCE discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners."

About IOTA

IOTA Pharmaceuticals provides FBDD-based molecular design, compound screening and lead discovery services to its partners in the pharmaceutical industry. For more information about IOTA, please visit

About Beactica

Beactica is a specialist drug discovery company, utilizing its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. For more information about Beactica, please visit


Dr David Bailey, CEO IOTA

Dr Per Kallblad, CEO Beactica

SOURCE IOTA Pharmaceuticals Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
2. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
3. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
4. Progen Restructures Manufacturing and Drug Discovery Divisions
5. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
6. Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery
7. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
8. BioCrossroads Launches and Releases Report on Biopharma Discovery and Development Contract Services
9. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
10. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
11. Xenon Announces Appointment of VP, Discovery Research
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 ... ... today announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform ... information to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust ...
(Date:11/28/2015)... ... 28, 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture ... , Bird Free, an oil-based, gel formula ... modalities including visual, smell, taste and touch, enabling safe, effective avian control without toxic ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to announce ... offered in symposia, oral sessions, workshops, awards, and posters. The core of ... applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):